Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.

The US subsidiary of South Korea’s HLB will take on the selective FGFR2 inhibitor.

Breyanzi and Imdelltra head up May’s approvals, while camrelizumab’s CRL is a lowlight.

ASCO is fast approaching, but in the meantime Olema will have an important readout.